抑郁症中的石胺:临床研究中的假定生物标志物
Jenessa N Johnston1, Carlos A Zarate1, Mark D Kvarta2
1Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA.
概括
埃斯凯特胺在治疗耐药性抑郁症 (TRD) 中提供快速抗抑郁作用. 需要进一步的研究来确定个性化治疗策略的生物标志物.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 精神病学是一个精神病学.
背景情况:
- 拉塞米克胺和胺显示出作为快速起作用的抗抑郁药物的前景.
- 埃斯凯特胺是FDA批准的治疗耐药性抑郁症 (TRD).
- 对乙胺反应的生物标志物研究是有限的,通常是从种族乙胺研究中推断出来的.
研究的目的:
- 审查当前对与胺胺抗抑郁作用相关的生物标志物的理解.
- 突出潜在的生物机制和神经成像相关的胺胺作用.
- 强调需要以生物标志物为重点的试验来个性化埃斯基他治疗的必要性.
主要方法:
- 对遗传学,蛋白质学,代谢学和神经成像学研究的文献评论.
- 对炎症,线粒体功能和大脑区域的初步发现进行分析.
- 检查外围生物标志物,如来自大脑的神经营养因子和血清素.
主要成果:
- 初步证据表明,胺胺在抗抑郁作用中的炎症和线粒体功能的作用.
- 神经成像涉及前额叶皮质,条纹体和前带皮质.
- 边缘生物标志物如BDNF和血清素与外科手术期间抗抑郁药/抗焦虑药效应相关.
结论:
- 石胺是TRD的一个有价值的工具,在其他环境中也有潜力.
- 进一步的研究对于验证初步生物标志物发现和理解机制至关重要.
- 以生物标志物为指导的临床试验对于个性化治疗必不可少.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
215
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
215
Sedatives and Hypnotics Drugs: Miscellaneous Agents
166
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
166
Electroconvulsive Therapy
31
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
31


